Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening.
Varicose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures.
This study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.

开始日期2024-01-22

申办/合作机构

Imperial College London

NCT05625932

/ Unknown status临床3期IIT

Prophylaxis of Venous Thromboembolic Disease With Low Molecular Weight (LMWH) (TINzaparin) in Patients With Metastatic Colorectal Cancer Who Start the First Line of Treatment.

Patients with metastatic colorectal cancer (mCRC) who are scheduled to receive systemic cancer therapy have an increased risk for venous thromboembolic (VTE) events compared with the general population.
PROTINCOL is a randomized, open label, non placebo-controlled, low intervention, and phase III clinical trial that will recruit patients with mCRC. The study hypothesizes that prophylaxis with Tinzaparin could prevent the appearance of symptomatic and incidental VTE.
All patients will receive the first-line anticancer treatment deemed more appropriate according to the physician criteria. Enrolled patients are randomized in a 1:1 ratio (stratifying by BRAF/RAS, resection of primary tumor, and anti-angiogenic first-line treatment) to: control arm (no interventions related to VTE risk and no placebo) or experimental arm (prophylactic Tinzaparin at a fixed dose of 4500 IU/day in patients with up to 80kg, 6000 IU/day for those between 80-100 kg, or 8000 IU/day for those >100kg). Treatment is scheduled for a maximum period of 4 months. Treatment could be stopped earlier in case of unacceptable toxicity, patient consent withdrawal, physician criteria or end of study. Patients will undergo tumor and VTE assessments according to standard clinical practice.
The main objective of the study is to evaluate the efficacy of tinzaparin for the prevention of symptomatic or incidental VTE events. Secondary objectives include the associations between VTE events and tumor characteristics (i.e. laterality, RAS/BRAF mutations) or management (i.e. surgery or treatment with anti-angiogenic or anti-EGFR agents), cancer-specific survival outcomes, safety, the incidence of bleeding events, and patient-reported quality of life. The trial includes also a translational exploratory analysis to assess the predictive value of risk assessment models and genetic risk scores, their evolution through the study and microsatellite instability or other biomarkers.

开始日期2023-03-02

申办/合作机构

Leo Pharma, Inc.

NCT05255003

/ Recruiting临床4期IIT

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding. This is especially a concern when the number of platelets in the blood is lower than 50,000 per microliter. The role of platelets is to stop bleeding, so when the number of platelets is low, patients are at a higher risk of bleeding. Cancer patients are prone to have lower platelet numbers due to cancer therapies and/or cancer itself. It is not clear what the best treatment is for cancer patients who need blood thinners for a blood clot but have low platelet counts.
The investigators plan to do a small study called a pilot study to help plan for a larger study in such patients. In the pilot study, investigators will include 50 patients with cancer, low platelet counts, and a blood clot diagnosed within 4 weeks. Patients will be randomly assigned to one of the two treatment strategies: the full dose of blood thinners along with platelet transfusion or a reduced dose of blood thinners without platelet transfusion. The investigators will follow all patients for 90 days. If this pilot study is successful, it will help lead to a much larger trial, which will provide important information on the best treatment strategy in these patients.

开始日期2022-08-29

申办/合作机构

Ottawa Hospital Research Institute

100 项与亭扎肝素钠相关的临床结果

登录后查看更多信息

100 项与亭扎肝素钠相关的转化医学

登录后查看更多信息

100 项与亭扎肝素钠相关的专利（医药）

登录后查看更多信息

527

项与亭扎肝素钠相关的文献（医药）

2025-06-01·THROMBOSIS AND HAEMOSTASIS

Risk of Recurrent Venous Thromboembolism in Patients with Cancer: An Individual Patient Data Meta-analysis and Development of a Prediction Model

Article

作者: Takada, Toshihiko ; Young, Annie M. ; van Es, Nick ; Di Nisio, Marcello ; Marshall, Andrea ; Raskob, Gary E. ; Büller, Harry R. ; Kamphuisen, Pieter W. ; Grosso, Michael A. ; Lanting, Vincent R. ; Bosch, Floris T. M. ; Lee, Agnes Y. Y.

Abstract:

About 7% of patients with cancer-associated venous thromboembolism (CAT) develop a recurrence during anticoagulant treatment. Identification of high-risk patients may help guide treatment decisions.To identify clinical predictors and develop a prediction model for on-treatment recurrent CAT.For this individual patient data meta-analysis, we used data from four randomized controlled trials evaluating low-molecular-weight heparin or direct oral anticoagulants (DOACs) for CAT (Hokusai VTE Cancer, SELECT-D, CLOT, and CATCH). The primary outcome was adjudicated on-treatment recurrent CAT during a 6-month follow-up. A clinical prediction model was developed using multivariable logistic regression analysis with backward selection. This model was validated using internal–external cross-validation. Performance was assessed by the c-statistic and a calibration plot.After excluding patients using vitamin K antagonists, the combined dataset comprised 2,245 patients with cancer and acute CAT who were treated with edoxaban (23%), rivaroxaban (9%), dalteparin (47%), or tinzaparin (20%). Recurrent on-treatment CAT during the 6-month follow-up occurred in 150 (6.7%) patients. Predictors included in the final model were age (restricted cubic spline), breast cancer (odds ratio [OR]: 0.42; 95% confidence interval [CI]: 0.20–0.87), metastatic disease (OR: 1.44; 95% CI: 1.01–2.05), treatment with DOAC (OR: 0.66; 95% CI: 0.44–0.98), and deep vein thrombosis only as an index event (OR: 1.72; 95% CI: 1.31–2.27). The c-statistic of the model was 0.63 (95% CI: 0.54–0.72) after internal–external cross-validation. Calibration varied across studies.The prediction model for recurrent CAT included five clinical predictors and has only modest discrimination. Prediction of recurrent CAT at the initiation of anticoagulation remains challenging.

2025-05-01·AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Comparison of Prophylactic and Therapeutic Doses of Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease: The TASC Double-Blind Controlled Randomized Clinical Trial

Article

作者: Melica, Giovanna ; Mekontso Dessap, Armand ; Bartolucci, Pablo ; Razazi, Keyvan ; Da Silva, Daniel ; Delacroix, Isabelle ; Roux, Damien ; Maitre, Bernard ; Lopez-Sublet, Marilucy ; Arlet, Jean-Benoît ; Fartoukh, Muriel ; Michel, Marc ; Gendreau, Ségolène ; Katsahian, Sandrine ; Carpentier, Benjamin ; Loko, Gylna ; Guerin, Laurent ; Affo, Louis ; Guillaud, Constance ; Charles-Nelson, Anaïs ; Habibi, Anoosha ; Etienne-Julan, Maryse ; Lionnet, François ; Oziel, Johanna ; Ngo, Stéphanie

BACKGROUND:

Patients with sickle cell disease hospitalised for acute chest syndrome (ACS) are at high risk of in situ pulmonary microthrombosis. We evaluated whether therapeutic anticoagulation could shorten ACS duration.

METHODS:

TASC is a randomized, controlled, double-blind trial conducted in 12 French hospitals (December 2016-April 2021) in adult ACS patients with no initial thrombosis on chest computerised tomography with pulmonary angiogram. We randomised 172 patients (1:1) to receive either prophylactic or therapeutic doses of low-molecular-weight tinzaparin for 7 days. The primary efficacy outcome was time to ACS resolution. The primary safety outcome was major bleeding. Main secondary outcomes included parenteral opioids consumption, transfusion, mortality at hospital discharge, and hospital readmissions at 6 months.

FINDINGS:

The primary efficacy outcome, time to ACS resolution, analysed using a Cox model, was shorter with therapeutic anticoagulation than with prophylactic doses (hazard ratio 0.71; 95% CI: [0.51-0.99]; p=0.044). As a supplemental estimate, the restricted mean time to ACS resolution (over a 15-day horizon or discharge) was shorter with therapeutic doses (4.8±0.4 vs 6.1±0.5 days). The primary safety outcome (major bleeding) did not occur in either group. The cumulative dose of parenteral opioids was lower with therapeutic anticoagulation: (124 [80;272] vs 219 [65;378] mg morphine equivalent, difference: -96, 95%CI: -202 to -46, p=0.02). Other short- and long-term secondary outcomes were similar between groups.

INTERPRETATION:

In adult patients with ACS, a therapeutic anticoagulation shortened ACS duration and reduced opioids consumption compared with prophylactic doses, without increasing bleeding risk. Clinical trial registration available at www.

CLINICALTRIALS:

gov, ID: NCT02580773.

2025-04-01·ACTA ANAESTHESIOLOGICA SCANDINAVICA

Preferences for thromboprophylaxis in the intensive care unit: An international survey

Article

作者: Nassef, Mohamed ; Orde, Sam ; Ananthan, Prakkash Parangi ; Krag, Mette ; Meijer, Karina ; Mallat, Jihad ; Pilcher, David ; Omar, Rania ; Meyhoff, Tine Sylvest ; Bestle, Morten H. ; Heijkoop, Èmese Robin Hélène ; Ergan, Begum ; Alshamsi, Fayez ; Bhadange, Neeraj ; Troelsen, Thomas Tværmose ; Aslam, Tayyba Naz ; Poulsen, Lone Musaeus ; Ferrer, Ricard ; Al‐Fares, Abdulrahman A. ; Marella, Prashanti ; Hjortrup, Peter Buhl ; Anstey, Matthew H. ; Sigurdsson, Martin Ingi ; Eck, Ruben Julius ; Siegemund, Martin ; Blaser, Annika Reintam ; Nalos, Marek ; Mer, Mervyn ; Ostermann, Marlies ; Greco, Massimiliano ; van Haren, Frank M. P. ; Arabi, Yaseen M. ; Attokaran, Antony George ; Ho, Kwok M. ; Freebairn, Ross ; Jonmarker, Sandra ; Rai, Sumeet ; Brøchner, Anne Craveiro ; Kruger, Peter ; Young, Paul ; Elhoufi, Ashraf ; Morgan, Matthew ; Rasmussen, Bodil Steen ; Perner, Anders ; Abdelhadi, Adel ; Keus, Frederik ; Dąbrowski, Wojciech ; Shekar, Kiran ; al Shirawi, Nehad Nabeel Mohamed ; Fujii, Tomoko ; Andreasen, Anne Sofie ; Malbrain, Manu L. N. G. ; Hildebrandt, Thomas ; Møller, Morten Hylander ; Cronhjort, Maria

Abstract:

Background:

Venous thromboembolism (VTE) is a frequent complication in critically ill patients, who often have multiple risk factors. Pharmacological thromboprophylaxis is widely applied to lower this risk, but guidelines lack dosing recommendations.

Objective:

This survey aims to assess current thromboprophylaxis preferences and willingness to participate in future randomized clinical trials (RCTs) on this topic.

Method:

We conducted an international online survey between February and May 2023 among intensive care unit (ICU) physicians, including 16 questions about preferences in relation to thromboprophylaxis and preferences on topics for a future RCT. The survey was distributed through the network of the Collaboration for Research in Intensive Care.

Results:

A total of 715 physicians from 170 ICUs in 23 countries contributed information, with a mean response rate of 36%. In most ICUs, both pharmacological (n = 166, 98%) and mechanical thromboprophylaxis (n = 143, 84%) were applied. A total of 36 pharmacological thromboprophylaxis regimens were reported. Use of low‐molecular‐weight heparin (LMWH) was most common (n = 149 ICUs, 87%), followed by subcutaneous unfractionated heparin (n = 44 ICUs, 26%). Seventy‐five percent of physicians indicated that they used enoxaparin 40 mg (4000 IU), dalteparin 5000 IU, or tinzaparin 4500 IU once daily, whereas 25% reported the use of 16 other LMWH type and dose combinations. Dose adjustment according to weight was common (78 ICUs, 46%). Participants perceived high variation in the application of thromboprophylaxis and were willing to consider an alternative LMWH type (n = 542, 76%) or dose (n = 538, 75%) in the context of an RCT.

Conclusion:

LMWH was the preferred agent for thromboprophylaxis in critically ill patients. There was considerable variation in the application of LMWH for prophylaxis, reflected by the use of different types, doses, and dosing strategies. Most physicians would be willing to participate in an RCT on thromboprophylaxis.

Editorial comment:

This survey demonstrates current patterns in implementation preferences for critically ill patients. While there is one approach and drug that is commonly preferred, these findings show that there is some variation in practice.

项与亭扎肝素钠相关的新闻（医药）

2025-07-17

·FiercePharma

Leo Pharma's slow response to app lapse scolded by UK marketing watchdog

Leo Pharma accepted that “appropriate actions were not taken to rectify the issue immediately” with its Innohep app. Leo Pharma’s inaccurate Innohep app has prompted a slap-down from the PMCPA. The U.K. marketing watchdog ruled Leo brought discredit on the pharma industry by leaving the app live for three months after the errors were discovered. Two healthcare professionals complained to the PMCPA about an app for patients prescribed Innohep, Leo’s tinzaparin sodium product. The app presented information from the patient information leaflet, and users were prompted to select their prescribed dosage and shown information on injection technique.Both complainants flagged inaccuracies in the dosing information presented in the app. A Leo employee identified the errors in August 2024, and Leo’s medical affairs team learned of the inaccuracies the next day, according to the PMCPA report, yet the app was still available when the PMCPA contacted Leo in November. Leo deactivated the app and made an updated version available within two weeks of being contacted by the PMCPA.Responding to the marketing authority, Leo said two senior medical affairs employees concluded that the full volume of the syringe would always be administered, despite any conflicting information in the app, and, as such, the inaccuracies didn’t affect patient safety. The PMCPA panel took a dim view of Leo’s conclusion, stating that inaccurate dosing information is a serious matter regardless of the likelihood of a safety issue. The panel said it “was extremely concerned about Leo Pharma’s lack of urgency” and the company’s “conscious decision to keep the app live with the inaccuracies for approximately three months.” The dosage volume inaccuracies and failure to withdraw the app immediately could “reduce confidence in the industry being able to produce patient material to the required quality standards,” the panel said.Leo accepted that “appropriate actions were not taken to rectify the issue immediately.” The company listed mitigating factors that may have played a role in the failings, including a disruption that affected the company from July, when the app was certified, to October, when Leo was still working through its response to the inaccuracies. “At the time of this issue occurring there was a reorganization of the thrombosis business impacting resource and headcount; many colleagues’ roles were placed at risk of redundancy. There was no dedicated medical support for the U.K. thrombosis business at this time,” Leo said. “Whilst this does not negate the seriousness of the issue and decisions made, we believe this to be a contributing factor.”The PMCPA appeal board opted against imposing additional sanctions on Leo. The board reached the decision after assessing Leo’s work to enhance its governance, train staff and update its processes to add checks and scrutiny. Leo said “it was not experienced with creating and managing apps and had relied on external expertise,” according to the PMCPA, and would act differently if in the same situation today.

专利侵权

2023-11-06

·PRNewswire

Global Antithrombotic/Anticoagulant Drugs Market Set to Reach $46.2 Billion by 2028 with a 7.9% CAGR

DUBLIN, Nov. 6, 2023 /PRNewswire/ -- The "Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global antithrombotic/anticoagulant drugs market is expected to reach $46.2 billion in 2028 from $31.6 billion in 2023 at a CAGR of 7.9%. This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market. This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028. Companies Mentioned Bayer AG Boehringer Ingelheim International GmbH Bristol Myers Squibb Daiichi Sankyo Co. Ltd. F. Hoffmann-La Roche Ltd. Johnson & Johnson Services Inc. Merck & Co. Inc. Pfizer Inc. Sanofi Report Includes 59 data tables and 35 additional tables Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19 A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration Profiles of the leading market players The following are the main conclusions reached in this report regarding antithrombotic and anticoagulant drugs: Recent innovations and the emergence of novel thrombin inhibitors have led to the decrease in revenue of traditional anticoagulants such as heparin and Vitamin K antagonists. Low molecular weight heparins, such as Fragmin (-11.8%) and Innohep (-14.1%), have seen a significant decrease in the market. The anticoagulant drug market will continue to grow at a slow rate compared to antiplatelet and thrombin inhibitors segment due to the lack of new drug launches since the expiration of the patent on Plavix. The anticoagulant segment is expected to decline soon as prices fall and the market for novel thrombin inhibitors grows. The market for thrombin inhibitors is expected to grow at the highest CAGR of 8.1% over the forecast period of 2023 to 2028. Xarelto (rivaroxaban), Eliquis (apixaban), TNKase (tenecteplase) and Savaysa (edoxaban) are the major contributors to the high growth rate of thrombin inhibitors. An aging population and the increased prevalence of cardiovascular disease worldwide fueled by a Westernized diet and lifestyle have created new opportunities for antithrombotic/ anticoagulant drug products. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Market Outlook Market Summary Chapter 3 Market Overview Overview of Cardiovascular Disease Coronary Artery Disease Atherosclerosis Angina (Angina Pectoris) Acute Myocardial Infarction Medical Management Lifestyle Changes Diet Modification Smoking Cessation Pharmaceuticals Anticoagulants and Antiplatelet Drugs Major Drivers Coagulation Factors Targeted to Reduce Cvd The Global Burden of Cardiovascular Disease 2030 Global Burden of Cardiovascular Disease The Global Economic Burden of Cardiovascular Disease Sales Performance of Major Drugs in 2022 Chapter 4 Global Market for Anticoagulant Drugs Overview Products Low Molecular Weight Heparin Oral Anticoagulants (Vitamin K Antagonists) Global Anticoagulant Drugs Market Forecast Chapter 5 Global Market for Antiplatelet Drugs Overview Products Oral Antiplatelets Global Antiplatelet Drugs Market Forecast Chapter 6 Global Market for Thrombin Inhibitors Overview Products Direct Thrombin Inhibitors Thrombolytic Agents Direct Factor Xa Inhibitors Global Thrombin Inhibitors Market Forecast Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region Overview North America Europe Asia-Pacific Rest of the World Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective Introduction to ESG Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective Key ESG Issues Consumer Attitudes Towards ESG Industry ESG Performance Analysis Case Study Concluding Remarks Chapter 9 Clinical Trials and Patent Landscape Clinical Trials Analysis Patent Analysis Patent by Assignee Chapter 10 M&A and Venture Funding Outlook Chapter 11 Competitive Landscape Chapter 12 Company Profiles Chapter 13 Appendix For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 项与亭扎肝素钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06398	亭扎肝素钠	B01AB10	DB06822

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肺栓塞	美国	LEO Pharma A/S	2000-07-14
静脉血栓形成	美国	LEO Pharma A/S	2000-07-14
血栓形成	加拿大	Novo Nordisk Canada, Inc.	1994-12-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISTH2022	N/A	浅表血栓性静脉炎	147	tinzaparin	積顧獵廠築衊觸艱選夢(積廠築觸獵窪簾夢鹽餘) = 構觸窪襯獵願網壓襯艱築築鏇範窪蓋糧艱範蓋 (獵選鬱齋鏇顧艱膚衊襯 )	-	2022-07-09
Onco-CAST (ASCO2022)	临床4期	结直肠癌	175	Tinzaparin 8.000 Anti-Xa IU	選糧淵膚網膚鑰憲窪膚(蓋網鬱構窪鹹鹹鏇願糧) = 衊壓築齋鬱網襯壓襯鹹鑰壓選憲鬱構遞網簾艱 (獵窪壓選鹽範夢壓膚鏇, 2.3 ~ 8.8) 更多	-	2022-06-02
NCT01455831 (Periop-01, ASCO_GI2022) 人工标引	临床3期	结直肠癌	602	Tinzaparin Sodium (Extended peri-operative thromboprophylaxis)	築夢衊夢鏇鏇夢築簾構(衊窪蓋蓋簾築夢壓網壓) = 衊齋齋繭窪鏇網顧願選鑰蓋蓋繭顧鏇選簾壓積 (醖餘鏇鑰製壓築遞鏇鹹 ) 更多	非优	2022-01-19
NCT01455831 (Periop-01, ASCO_GI2022) 人工标引	临床3期	结直肠癌	602	Tinzaparin Sodium (Standard thromboprophylaxis)	築夢衊夢鏇鏇夢築簾構(衊窪蓋蓋簾築夢壓網壓) = 醖廠製艱襯積遞築窪鏇鑰蓋蓋繭顧鏇選簾壓積 (醖餘鏇鑰製壓築遞鏇鹹 ) 更多	非优	2022-01-19
iCaLT study (ERS2021)	N/A	肺癌	60	Tinzaparin 0.5 ml, 10.000 Anti-Xa IU	鏇壓餘獵鹹膚衊鹹艱鏇(範醖夢遞鑰膚糧觸蓋餘) = Low in patients with bleeding compared to others 鑰網製積網繭夢醖範窪 (齋餘襯選壓憲醖選範範 )	积极	2021-09-05
PROSPERO CRD42020139413 (ISTH2020)	N/A	慢性肾病	1,831	Tinzaparin	觸廠糧齋網壓觸糧糧構(構蓋繭網鑰鹹醖鏇鹹鑰) = 衊獵夢鹹獵窪積膚願壓構製獵願壓齋鬱願衊醖 (襯夢簾蓋廠齋膚顧襯築, (0.85 ~ 3.61)) 更多	-	2020-07-12
ISTH2020	N/A	静脉血栓栓塞	287	Weight-adjusted Tinzaparin	網糧鹹壓鑰網願繭蓋積(鬱遞餘構構顧夢衊範網) = 遞憲鏇鏇構構鹹製顧願淵鑰範選簾顧膚鬱鬱範 (衊餘餘夢淵餘壓獵鏇顧 )	-	2020-07-12
ISTH2020	N/A	静脉血栓栓塞	287	No prophylaxis or subcutaneous UFH	網糧鹹壓鑰網願繭蓋積(鬱遞餘構構顧夢衊範網) = 鏇蓋網構淵蓋憲遞醖糧淵鑰範選簾顧膚鬱鬱範 (衊餘餘夢淵餘壓獵鏇顧 )	-	2020-07-12
TROPIQUE (ISTH2020)	N/A	血栓形成	-	Long-term tinzaparin treatment	構窪鹹夢壓憲憲觸鏇鹽(蓋醖築醖遞壓獵築憲齋) = 築製獵膚構鹽衊襯顧簾製鑰廠鹹齋觸網構糧衊 (範遞積憲餘網觸範鹽顧 ) 更多	积极	2020-07-12
NCT00186745 (TRIVET, ASH 12016 \| ASH 22016) 人工标引	N/A	慢性肾病	148	Tinzaparin (1st measurement (Day 3-5))	鏇蓋餘鬱積願積鑰鑰齋(觸窪衊築醖願鑰鬱積網) = 淵鬱蓋鬱觸鹽製構願鏇醖憲簾顧壓獵襯鏇壓觸 (鹹夢窪簾築網築醖窪夢, 0.22) 更多	积极	2016-12-02
NCT00186745 (TRIVET, ASH 12016 \| ASH 22016) 人工标引	N/A	慢性肾病	148	Tinzaparin (2nd measurement (Day 5-7))	鏇蓋餘鬱積願積鑰鑰齋(觸窪衊築醖願鑰鬱積網) = 鹽壓糧窪鹹襯淵鹹願鏇醖憲簾顧壓獵襯鏇壓觸 (鹹夢窪簾築網築醖窪夢, 0.09) 更多	积极	2016-12-02
TiCAT study (ERS2016)	N/A	静脉血栓栓塞	246	Tinzaparin	鹽鏇廠鬱顧鹹簾憲構蓋(範糧鏇壓廠獵醖壓製襯) = 齋鏇簾鹹製蓋鑰繭淵憲艱夢築鏇積鬱鏇醖製齋 (構糧構繭蓋憲選艱選襯 ) 更多	积极	2016-09-01
NCT01130025 (IN 0901 INT, Pubmed \| J Coll Physicians Surg Pak \| JAMA) 人工标引	临床3期	肿瘤 \| 静脉血栓栓塞	900	Tinzaparin	齋衊選鬱鹽選鑰遞顧鹽(餘鏇糧構蓋願繭膚醖網) = 齋窪餘築遞觸淵遞艱壓齋遞餘鹽蓋願範選夢衊 (憲獵鏇衊築遞衊繭構觸 ) 更多	非优	2015-08-18
	临床3期	肿瘤 \| 静脉血栓栓塞	900	Tinzaparin+warfarin	齋衊選鬱鹽選鑰遞顧鹽(餘鏇糧構蓋願繭膚醖網) = 鑰艱醖積繭廠網夢鏇選齋遞餘鹽蓋願範選夢衊 (憲獵鏇衊築遞衊繭構觸 ) 更多	非优	2015-08-18